Maitake 'Hen of the Woods' (Grifola frondosa 'Hen of the Woods')

Maitake 'Hen of the Woods' (Grifola frondosa) contains a bioactive beta-glucan polysaccharide called D-fraction, which activates macrophages, natural killer cells, and T-cells through pattern recognition receptors such as Dectin-1. This immune modulation forms the basis for its studied antitumor and immunosupportive properties in preliminary clinical research.

Origin & History

Maitake 'Hen of the Woods' (Grifola frondosa) is a polypore mushroom native to China, Europe, and North America that grows at the base of old oaks or maples. This edible fungus is consumed as food in Asia and used medicinally, with bioactive extracts typically obtained via hot water extraction from the fruiting body, yielding polysaccharides as the primary chemical class.

Historical & Cultural Context

Maitake has centuries of use in traditional Asian medicine, particularly in Japan, as an immunostimulant for immune enhancement, diabetes, hypertension, and cancer prevention/treatment. It gained medicinal popularity in Japan for immune support alongside its role as an edible delicacy.

Health Benefits

• May support immune function in HIV patients - small open-label study showed increased CD4+ cell counts in 20 of 35 patients (preliminary evidence)
• Potential antitumor effects - noncontrolled study reported tumor regression or symptom improvement in half of cancer patients (very preliminary evidence)
• May help regulate blood sugar - demonstrated hypoglycemic activity in type 2 diabetes patients (limited evidence, study details not provided)
• Immunomodulation through beta-glucan activation of macrophages, NK cells, and T cells (primarily animal evidence)
• May reduce chemotherapy toxicity - animal studies showed reduced doxorubicin toxicity and mitomycin-C dosage needs (no human data)

How It Works

Maitake D-fraction, a proteoglucan beta-1,3/1,6-glucan, binds to Dectin-1 and complement receptor CR3 (CD11b/CD18) on macrophages and dendritic cells, triggering NF-κB signaling and upregulating pro-inflammatory cytokines including TNF-α, IL-12, and IL-1β. This cascade activates NK cells and cytotoxic T-lymphocytes, enhancing cell-mediated immune surveillance. Additionally, D-fraction has demonstrated inhibition of tumor cell proliferation via induction of apoptosis through caspase-3 activation in in vitro models.

Scientific Research

Human clinical evidence remains limited with no large RCTs or meta-analyses identified. A small noncontrolled cancer study reported tumor regression in half of subjects, while an open-label study of 35 HIV patients taking 250mg daily for 12 months showed increased CD4+ counts in 20 patients. No PubMed PMIDs were provided in the research sources.

Clinical Summary

A small open-label study in 35 HIV-positive patients found that oral maitake D-fraction supplementation increased CD4+ T-cell counts in approximately 57% of participants, though the lack of a control group severely limits interpretation. A separate noncontrolled observational study reported tumor regression or subjective symptom improvement in roughly 50% of cancer patients using D-fraction as an adjunct to chemotherapy. A phase I/II trial examining maitake whole extract in postmenopausal breast cancer patients (n=29) demonstrated measurable immunological stimulation at doses of 0.1–5 mg/kg, though clinical outcomes were not the primary endpoint. Overall, the evidence base consists largely of small, nonrandomized, or uncontrolled studies, making definitive efficacy conclusions premature.

Nutritional Profile

Per 100g fresh weight: Calories ~31 kcal, Protein ~1.9g (containing all essential amino acids including lysine and leucine), Carbohydrates ~6.9g, Dietary Fiber ~2.7g (predominantly beta-glucans, specifically (1→3)(1→6)-beta-D-glucans at approximately 15-30% of dry weight, notably the D-fraction/MD-fraction polysaccharides), Fat ~0.2g. Water content ~90%. Key micronutrients: Potassium ~204mg/100g, Phosphorus ~74mg/100g, Magnesium ~10mg/100g, Copper ~0.3mg/100g (notable concentration supporting enzymatic function), Zinc ~0.9mg/100g, Selenium ~2.2mcg/100g. Vitamins: Niacin (B3) ~6.6mg/100g (significant contributor to daily intake), Riboflavin (B2) ~0.24mg/100g, Pantothenic acid (B5) ~0.28mg/100g, Vitamin D2 (ergocalciferol) ~28 IU/100g when UV-exposed (dramatically increases with sun/UV exposure to potentially 400+ IU). Bioactive compounds: Grifolan (branched beta-glucan), ergosterol ~4.5mg/g dry weight (provitamin D2 precursor), ergothioneine (antioxidant amino acid) ~0.4mg/g dry weight, triterpenes including grifolic acid. Bioavailability notes: Beta-glucan bioavailability enhanced by cooking/hot water extraction; ergothioneine is highly bioavailable in humans via specific transporter OCTN1; Vitamin D2 bioavailability is approximately 70-80% relative to D3.

Preparation & Dosage

Clinically studied dosage: 250 mg dried maitake powder daily (combined with 5 mg vitamin C) for 12 months in HIV patients. Standardized extract dosages for D-fraction or MD-fraction have not been established in human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Reishi, Shiitake, Turkey Tail, Astragalus

Safety & Interactions

Maitake is generally well tolerated; reported adverse effects are mild and include gastrointestinal upset such as bloating and loose stools, particularly at higher doses. Because D-fraction can stimulate immune activity, individuals with autoimmune conditions (e.g., lupus, multiple sclerosis, rheumatoid arthritis) or those on immunosuppressant drugs such as cyclosporine or tacrolimus should consult a physician before use. Maitake may have additive hypoglycemic effects when combined with insulin or oral antidiabetic agents such as metformin, warranting blood glucose monitoring. Safety data in pregnancy and lactation are insufficient, so use is not recommended during these periods.